期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
1
作者 Ingmar Knigsrainer Derek Zieker +6 位作者 Jrg Glatzle Olivia Lauk Julia Klimek Stephan Symons Bjrn Brücher Stefan Beckert Alfred Knigsrainer 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第17期2061-2066,共6页
AIM:To investigate perioperative patient morbidity/mortality and outcome after cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC).METHODS:Of 150 patients 100 were treated with cytoreductiv... AIM:To investigate perioperative patient morbidity/mortality and outcome after cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC).METHODS:Of 150 patients 100 were treated with cytoreductive surgery and HIPEC and retrospectively analyzed.Clinical and postoperative follow-up data were evaluated.Body mass index(BMI),age and peritoneal carcinomatosis index(PCI) were chosen as selection criteria with regard to tumor-free survival and perioperative morbidity for this multimodal therapy.RESULTS:CRS with HIPEC was successfully performed in 100 out of 150 patients.Fifty patients were excluded because of intraoperative contraindication.Median PCI was 17(1-39).In 89% a radical resection(CC0/CC1) was achieved.One patient died postoperatively due to multiorgan failure.Neither PCI,age nor BMI was a risk factor for postoperative complications/outcome according to the DINDO classification.In 9% Re-CRS with HIPEC was performed during the follow-up period.CONCLUSION:Patient selection remains the most important issue.Neither PCI,age nor BMI alone should be an exclusion criterion for this multimodal therapy. 展开更多
关键词 Peritoneal carcinomatosis Single-center experience Hyperthermic intraoperative chemotherapy Complications risk assessment Selection criteria
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部